NBRV Nabriva Therapeutics AG

10.10
+0.10  (1%)
Previous Close 10.00
Open 10.02
Price To book 3.52
Market Cap 274.68M
Shares 27,196,000
Volume 12,484
Short Ratio 3.58
Av. Daily Volume 24,316

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to be completed 4Q 2017, with data due 1Q 2018.
Lefamulin - LEAP 2
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)
Phase 3 enrollment completion noted April 11, 2017 with data due 3Q 2017.
Lefamulin - LEAP 1
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)

Latest News

  1. Nabriva Commences Previously Announced Tender Offer Related to the Proposed Redomicile of its Holding Company from Austria to Ireland
  2. Nabriva Therapeutics Reports First Quarter 2017 Financial Results
  3. Nabriva Announces the Proposed Redomicile of its Holding Company from Austria to Ireland, by means of an Exchange Offer
  4. Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin
  5. Nabriva Therapeutics AG :NBRV-US: Earnings Analysis: 2016 By the Numbers : April 11, 2017
  6. Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia
  7. Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors
  8. Nabriva Therapeutics to Present at the Needham and Company 16th Annual Healthcare Conference
  9. Nabriva Therapeutics Provides Business and Development Update and Reports 2016 Financial Results
  10. Arbutus Announces Appointment of Daniel Burgess to Board of Directors
  11. Nabriva Therapeutics (NBRV) Catches Eye: Stock Gains 9.8%
  12. Nabriva Therapeutics to Present at the Cowen and Company 37th Annual Healthcare Conference
  13. A growing threat could kill 10 million people a year by 2050
  14. Ally Bridge Group Expands European Life Science Portfolio with New Investments and Establishes Presence in Europe
  15. BIOLASE Inc (BIOL): How It Stacks Up Against Its Peers